Medchemexpress LLC DCC-3116 | 2543673-19-2 | 99.7% | 535.60 | 50 MG

Supplier:  Medchemexpress LLC HY16069950MG

DCC-3116 is an orally active ULK1/2 inhibitor. It inhibits autophagy in lung cancer cells by targeting KRASG12C signaling, which in turn inhibits the proliferation of lung cancer cells and exhibits anti-cancer effects.

• Orally active ULK1/2 inhibitor.
• Inhibits autophagy in lung cancer cells by inhibiting KRASG12C signaling.
• Inhibits proliferation of lung cancer cells.
• Exerts anti-cancer effects.
• DCC-3116 (100 nM, 72 h) alone inhibits the proliferation of NCI-H2122 and Calu-1 cells, decreases the expression of pS318-ATG13, and shows synergistic effects when combined with Sotorasib.
• In mouse models of NSCLC lung cancer, DCC-3116 (3 or 30 mg/kg/day for 56 days, p.o. and p.i.) alone or in combination with Sotorasib can inhibit tumor growth and improve survival rate.

Catalog No. 50-003-94420